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Background: Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the adult mammalian
brain, but exerts physiologic effects other than that on neurotransmitter in non-neuronal peripheral tissues and
organs. GABA may affect cancer growth through activation GABA receptors. We investigated the gene expression
of GABA receptors in tissue of non-small cell lung cancers (NSCLC) and non-cancerous tissues, and found that the
gene expression of GABA receptor phenotypes was correlated with tumorigenesis and clinical prognosis.
Methods: Sixty-one snap-frozen human samples of NSCLC tissues and paired non-cancerous tissues (5cm away from
tumor) were analyzed. Gene expression of GABA receptors was detected by Real-time quantitative PCR (RT-qPCR).
Survival times in relation to the expression of GABA receptor phenotypes were analyzed. Human NSCLC cell lines
H1299, A549, H520, H460 and human bronchial epithelial cell line BEAS-2B were used to determine the
phenotypes of GABA inhibitory effects on cancer cell growth. The effects of exogenous administration of GABA on
H1299 cell growth were examined.
Results: The gene expressions were significantly higher in NSCLC tissues than in the paired non-cancerous tissues
for GABAA receptor subunit α3 (GABRA3, P = 0.030); for GABAA receptor subunit epsilon (GABRE, P = 0.036); and
GABAB receptor subunit 2 (GABBR2, P = 0.005). Kaplan-Meier curves showed that patients with high expression of
GABBR2 gene and low expression of GABRA3 gene had a better prognosis (P < 0.05). The administration of GABA
resulted in suppressed proliferation of NSCLC cell lines in a dose- and time-dependent manner. The use of the
GABA receptor antagonist CGP35348 could reverse the inhibitory effect.
Conclusions: The pattern of GABA receptor gene phenotype expression may be involved in the regulation of
tumorigenesis. A high expression of GABBR2 with a low expression of GABRA3 may predict a better outcome. The
treatment with GABA attenuates cancer cell growth in vitro. The expression of GABA receptor may be not only
promising genetic therapeutic targets but may also serve as valuable prognostic markers for NSCLC.
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Cancer is a major global public health problem. One in 4
deaths in the United States is due to cancer [1]. Lung can-
cer is comprising 17% of the total new cancer cases and
23% of the total cancer deaths [2]. Non-small cell lung
cancer (NSCLC) accounts for about 80% of all lung cancer
cases where adenocarcinoma is dominantly presented [3].
Conventional treatment of NSCLC has improved survival,
but the 5-year survival rate is approximately 16% over the
past 30 years [1]. Novel and effective methods are urgently
required for lung cancer therapy.
Gamma-aminobutyric acid (GABA) is the main inhibi-
tory neurotransmitter in the adult mammalian brain via
activation of specific GABA receptors highly expressed in
the central nervous system (CNS) [4,5]. GABA receptors
are composed of GABAA and GABAB receptors. GABAA
receptors are ligand-gated chloride channels composed of
five subunits. These subunits are encoded by 19 different
genes that have been grouped into eight subclasses based
on sequence homology (α1–6, β1–3, γ1–3, δ, ε, θ, π, ρ1–3).
GABAB receptors are heterodimeric G-protein-coupled
receptors (GPCRs) composed of GABBR1 and GABBR2
subunits which are both required for normal receptor
functioning [6].
It has recently revealed that GABA and its receptors
also exist in non-neuronal peripheral tissues and organs,
indicating that GABA exerts physiologic effects other than
the inhibitory neurotransmitter property. In fact, GABA
has been shown to be involved in the development of
many tissues and organs, including the peripheral nervous
system [7], the development of the palate [8], lung [9],
pancreas [10], digestive tract [11], liver [12], chondrocytes
[13], testicular cells [14] and even stem cells [15].
Given that GABA participates in the proliferation of
various normal cell types and tissues, it is intriguing to
consider the potential function of GABA in cancer cells.
Recent studies gave the evidences that GABA and its re-
ceptors seemed to play critically regulative effects on many
kinds of cancers [12,16-31]. In most cases, the levels of
GABA receptors accompanying other growth signaling
components had significant changes in cancer cells. This
raised the possibility that manipulating GABA receptor
activity might inhibit tumor growth [25].
In this study, we tested the hypothesis that GABA
receptor profiles modulate cancer survival. We thus in-
vestigated the gene expression of GABA receptor phe-
notypes in NSCLC tissues and paired non-cancerous
tissues obtained from surgical patients to correlate the
GABA receptor gene profiles with clinical outcome. To
examine the specific effects of GABA receptor on lung
cancer cell growth, we investigated the GABA receptor
profiles in cancer cell lines and in normal human epithelial
cell line in the presence and absence of exogenous adminis-
tration of GABA.Methods
Cancer cell lines
Human NSCLC cell lines H1299(adenocarcinoma), A549
(adenocarcinoma), H520(squamous cell carcinoma), H460
(large cell carcinoma) and normal human bronchial epithe-
lial cell line BEAS-2B (ATCC, Rockville, Maryland) were
cultured at 37°C with 5% CO2 in DMEM (Gibco, Beijing,
China) supplemented with 10% FBS (Gibco, Beijing, China)
without antibiotics.MTT assays for cell proliferation
To measure the proliferation of cells, the colorimetric 3-
(4, 5-dimethyle thiazol-2-yl)-2, 5-diphenyl tetrazolium
bromide (MTT) assays (Sigma) were used in vitro. In the
MTT assays, cells were seeded into 96-well plates (2 × 103
cells per well), grown overnight, washed in PBS, and incu-
bated with GABA (Sigma-Aldrich) at 0.1 μmol/L to 500
μmol/L in the presence or absence of 100 μmol/L picro-
toxin (PTX, GABAA receptor antagonist) or CGP35348
(CGP, GABAB receptor antagonist), respectively. MTT
was then added (10ug/well) for 4h. Formazan products
were solubilized with DMSO, and the optical density was
measured at 490 nm.Tissues and subjects
Sixty-one samples of NSCLC tissues and paired non-
cancerous tissues (5cm away from tumor) were collected
from the Thoracic Cardio Surgery Department of the First
Affiliated Hospital of Guangzhou Medical College under
full ethical clearance by the Guangzhou Medical College
Ethics Committee for experimentation on human subjects.
Informed written consent was obtained from the partici-
pants. All subjects were Chinese. The collected samples
were immediately cut into small pieces and snap-frozen in
liquid nitrogen until further use. All tumor tissue and
paired non-cancerous tissue samples were pathologically
confirmed.RNA extraction and cDNA synthesis
Total RNA from cell lines and liquid-nitrogen-frozen
NSCLC tissue samples were extracted using Trizol reagent
(Invitrogen). First-strand cDNAs were synthesized using
primerscript RT reagent kit (Takara). Briefly, a mix of 2 ug
RNA, 2 μl of 5× gDNA eraser buffer and 1 μl of gDNA
eraser in a final volume of 10 μl with RNase free DH2O,
was incubated at 42°C for 2 min to get rid of gDNA, and
placed on ice for at least 1 min. Then 4 μL 5× Primerscript
buffer, 1 μL Primerscript RT enzyme mix I, 1 μL RT pri-
mer mix, and 3 μL RNase free DH2O were added, and in-
cubated at 37°C for 15 min followed by 85°C for 5 sec.
The cDNA samples were stored at −20°C until use.
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Primers were designed using Primer Premier 5.0 and
oligo 7 Software. Each primer pair was verified for gene
specificity using Nucleotide Basic Local Alignment
Search Tool from the GenBank non-redundant nucleotide
sequence database (National Centre for Biotechnology In-
formation, 2009, http://www.ncbi.nlm.nih.gov/). The se-
quence of each primer pair and the expected amplicon
size were summarised in Table 1.
PCR
PCR was performed to pick out the genes expression in
NSCLC cancer cell lines using Premix Taq® version 2.0 kit
(Takara). The reaction condition was followed: initial de-
naturation at 95°C for 1 min; 35 cycles of 30 sec at 95°C;
30 sec at 58°C; and 30 sec at 72°C; followed by a final 3
min extension at 72°C. 3% Agarose gel was used in elec-
trophoresis to separate the reaction products at 80V,
40min. After dyeing with ethidium bromide, the Gel Doc™
EZ Imager (BIO-RAD) was used for imaging.
RT-qPCR
Real-time quantitative PCR was carried out in tissues
cDNA samples using the SYBR® Premix Ex Taq™ reagent
kit (Takara) through ABI PRISM®7900 HT Fast Real-Time
PCR system (Applied Biosystems). Briefly, 2 μl of each
cDNA product was amplified in a mixture containing 12.5
μl of 2 × SYBR® Premix Ex Taq™, 0.5 μl of 10 μmol/L PCR
sense primer and the same quantitative antisense primer
with dH2O in a final volume of 25 μL. The RT-qPCR was
performed using the following parameters: initial denatur-
ation at 95°C for 30 sec, 40 cycles of 5 s at 95°C, 30 s at
60°C. The dissolved curve was added to verify the specifi-
city of amplified products. Wells with no template wereTable 1 Primer sequences, NCBI gene ID and amplicon size













18S rRNA 100008588 Sense
Antisenseincluded for each primer set as a negative control. In each
experiment, samples were amplified in duplicate for each of
the genes of interest and the reference gene. Only average
CT values with a standard deviation <0.5 were accepted.Statistic analysis
The expression of each gene of interest was determined in
relation to the reference gene 18S rRNA. The difference
in the mean CT values of the duplicate samples against
the reference gene was calculated to give the ΔCT. The
relative quantitation value was then expressed as two
times -ΔCT (2–ΔCT). Analysis of the 2–ΔCT values data was
performed using SPSS 13.0 followed by Paired-Samples t
Test and Independent-Samples t Test where appropriate.
Correlation analysis was carried out for GABA concentra-
tion and cell growth over time. Survival times between
groups were displayed by Kaplan-Meier curves after a log-
rank test. P<0.05 was considered statistical significance.Results
Effect of GABA on cancer cell proliferation
To examine the effects of administration of exogenous
GABA on cancer cells proliferation in vitro, MTT assays
were performed on the H1299 cells at broad range of
concentrations of GABA(0.1-500 μmol/L). There was a
dose- and time-dependent inhibition of cell proliferation
with GABA (Figure 1A, B). The GABA concentration
used was negatively correlated with the proliferation index
(Figure 1C, r = −0.778, p < 0.001; Figure 1D, r = −0.876,
p < 0.001). This inhibitory effects of GABA on cell prolif-
eration was blocked by the use of CGP, a GABAB receptor
antagonist, while PTX, a GABAA receptor antagonist, had















Figure 1 The effects of GABA and GABA agents on NSCLC cell. H1299 cell proliferation was suppressed by GABA in a dose-dependent
manner measured by MTT assays (Figure 1A and C). The inhibitory effects of GABA (100 μM/L) on H1299 cell growth were time-dependent
(Figure 1B and D). This inhibitory effects of GABA (100 μM/L) on H1299 cell growth was blocked by CGP co-cultured but not by PTX (Figure 1E
and F). Proliferation index was calculated as the ratio of the absorbance of cells incubated with GABA or GABA agents compare with negative
controls (NC) which was defined as the cells cultured only with complete medium. N =3. *P < 0.05, ** P < 0.01, *** P < 0.001 vs NC.
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not show).
GABA receptor profiles in NSCLC cell lines
The mRNA profile of GABA receptors was determined
in NSCLC cell lines including H1299, A549, H520,H460 and BEAS-2B. The mRNA of human brain (a kind
gift from Dr. He Junde, Department of neurosurgery in
the same affiliation as ZX) was used as positive control
and the normal lung bronchiolial epithelial cells BEAS-2B
served as negative control. We found that six GABA re-
ceptor subunits were expressed in most NSCLC cell lines
Figure 2 (See legend on next page.)
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Figure 2 The mRNA profile of GABA receptors in NSCLC cell lines. Figure 2A show that GABRA3, GABRB3, GABRE, GABRP, GABBR1 and GABBR2
ecpress in NSCLC cell lines. Brain expression acts as a positive control and BEAS-2B as a negative control. Figure 2B show three times of the PCR
for gene relative expression. * P < 0.05, ** P < 0.01.
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GABRE, GABRP) and GABAB receptor subunits (GABBR1
and GABBR2) (Figure 2A and B).
GABA receptor profiles in NSCLC tissues and paired non-
cancerous tissues
The gene expression of GABRA3, GABRE and GABBR2 was
significantly higher in primary NSCLC tissues than in the
paired non-cancerous tissues (GABRA3, t = 2.227, P = 0.030;
GABRE, t = 2.148, P = 0.036; GABBR2, t = 2.928, P = 0.005;
Figure 3A, B and C). There was no significant differ-
ence observed in the expression of GABRB3 (t = −0.330,
P = 0.742), GABRP (t = 1.072, P = 0.288) or GABBR1
(t = −0.326, P = 0.746, Figure 3D, E and F) in the same tis-
sues examined (Table 2).
Survival analysis in relation to GABA receptor gene
profiles
Using the median of 2-ΔCT value as cutoff point, the data
was divided into high and low expression for analysis. AFigure 3 Gene expression levels in all NSCLC tissues and paired non-
expression of 18S rRNA acts as reference gene. There is a significant increa
0.036, Figure 3B) and GABBR2 (**P = 0.005, Figure 3C) in NSCLC tissues, with
(P = 0.288, Figure 3E) and GABBR1 (P = 0.746, Figure 3F). * P < 0.05, ** P < 0.0high expression of GABBR2 in the lung tissue was asso-
ciated with better survival as compared to those where low
expression was detected (Figure 4B). However, a higher ex-
pression of GABRA3 was associated with a lower survival
rate (Figure 4A). Smoking and TNM stage were also the
important influential factors of decreased survival
(Figure 4E, F). Expression of GABRE and pathological
grade did not appear to influence on survival time
(Figure 4C, D).GABA receptors profiles and selected clinical
characteristics
The gene expression of GABRA3 was significantly higher in
the NSCLC tissues in male patients, while the expression of
GABBR2 was significantly higher than paired controls in
the patients of female (Table 3). It appeared that the gene
expression of both GABRA3 and GABBR2 was higher in the
patients with early stage of pathology, but not in the ad-
vanced stages.cancerous tissues. Relative expression is presented as 2-ΔCT ± S.E. The
se in gene expression for GABRA3 (*P = 0.030, Figure 3A), GABRE (*P =
no difference in expression for GABRB3 (P = 0.742, Figure 3D), GABRP
1.
Table 2 Comparison of GABA receptor gene relative
expression between cancer and paired non-cancerous
tissue
Normal(n = 61) Cancer(n = 61) P value
GABRA3 1.647 ± 0.394 3.681 ± 0.853 0.030*
GABRE 2.054 ± 0.276 3.767 ± 0.883 0.036*
GABBR2 0.940 ± 0.236 3.315 ± 0.868 0.005**
GABRB3 3.585 ± 1.163 3.103 ± 0.792 0.742
GABRP 3.147 ± 0.475 4.095 ± 0.760 0.288
GABBR1 3.693 ± 0.538 3.413 ± 0.976 0.746
The data of GABA receptor gene relative expression were expressed as mean
± SE. Normal: Paired non-cancerous tissue. * P < 0.05, ** P < 0.01.
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GABA and GABA receptors act as an inhibitory neuro-
transmitter in the mature CNS, but their functions in
non-neuronal cells or tumor cells are not well addressed.
Previous investigation has reported that GABA is signifi-
cantly decreased in NSCLC tissues [26]. The previous
observation maybe explained by our current findings
demonstrating that GABA exerts inhibitory effects on hu-
man NSCLC cell. Our results further demonstrate that
GABAB receptors play an important role in mediating the
GABA-inhibitory effects on NSCLC cells since the effects
were blocked by using the antagonist CGP35348 specific
for GABAB receptor. Decreased GABA level might have
resulted in impaired inhibitory effects on cancer cell pro-
liferation as seen clinically [26]. A compensatory mechan-
ism may be required by enhancing the expression of
GABAB receptors in order to redeem the impaired inhibi-
tory effects.
The etiological factors of lung cancer are still not clear,
but the tumor progression is associated with genetic
changes and is reflected in phenotypic changes such as
altered gene expression profiles. In this study, we found
that the six genes of GABA receptors are expressed in
most of NSCLC cells and tissues, including GABRA3,
GABRB3, GABRE, GABRP, GABBR1 and GABBR2. These
subunits might compose functional GABAA and GABAB
receptor. These genetic changes suggest that GABA re-
ceptors have close relationship with NSCLC progression.
As for GABAB receptors, it is now well accepted that
GABAB receptors assemble into heteromers composed
of one GABBR1 and one GABBR2 subunit, which are
both required for normal receptor function [6,32]. Some
recent reports have suggested that GABA inhibits neo-
plastic proliferation via GABAB receptor [23,26]. Since
GABAB receptor could strongly inhibit base level and
isoproterenol-induced cAMP, p-CREB, cyclic adenosine
monophosphate response element-luciferase activity and
p-extracellular regulated kinase-1 (ERK1)/2 and effect-
ively blocked DNA synthesis and cell migration. The
inhibitory cancer cells arrest in G(0)/G(1) phase which isassociated with down-regulation of intracellular cAMP
level [33]. In our study, GABA inhibited proliferation of
NSCLC cells in a dose-dependent and a time-dependent
manner. This inhibitory effect could be blocked in the
presence of GABAB receptor inhibitor CGP35348. How-
ever, co-cultured with GABAA receptor inhibitor picro-
toxin, there were no significant proliferative effects on
cancer cells versus control. These results imply that GABA
inhibition of NSCLC cell proliferation was associated with
GABAB receptor which coincides with the report by
Schuller and Al-Wadei [23,26]. The high level expression
of GABAB receptor gene in NSCLC tissues compared with
the adjacent non-tumor lung tissues, implicated that
GABA and GABAB receptor pathways could be a critical
factor in regulation of NSCLC cells proliferation. This
pathway might be a promising molecular target for the de-
velopment of new therapeutic strategies for antineoplaston.
As for GABAA receptors, it has been demonstrated that
GABAA receptors are usually composed of two α subunits,
two β subunits, and one γ subunit, and sometime the γ
subunit is replaced by other subunits, such as δ, ε, π and θ
[34]. Different GABAA receptor subunits have been
detected in many cancer cell lines and tissues. Li et al. [12]
detected overexpression of GABRQ in hepatocellular car-
cinoma cell line HepG2, and half of the tested hepatocel-
lular carcinoma tissues. Takehara [35] identified the
overexpression of GABA receptor pi subunit (GABRP) in
PDAC cells. In gastric cancer, more than five GABAA re-
ceptor subunits were associated with stimulating KATO
III cells [28]. The similar results that GABAA receptors
are related to cancer cell proliferation were reported in
prostate cancer [29], breast carcinoma [36], even in nor-
mal human small airway epithelial cells [37]. These find-
ings imply that the inward Cl— ionic current transport
and the activated mitogen-activated protein kinase/extra-
cellular signal-regulated kinase (MAPK/Erk) cascade via
GABAA receptors positively promotes cell proliferation.
Our study revealed that the GABRA3 receptor gene was
overexpression in NSCLC tissues compare with paired
non-cancerous tissues, this was consistent with the study
reported by Liu et al. [38]. In addition, beside overex-
pression of GABRA3 and GABRE genes, the other GABAA
receptor genes expression in our study including GABRB3
and GABRP were also detected in lung cancers, although
there was no significant difference between NSCLC tissues
and paired non-cancerous tissues. These GABAA receptor
subunits may form a functional pentameric chloride chan-
nel. We observe that the overexpression GABRA3 and
GABRE genes were not associated with proliferative effects
on cancer cells. This indecipherable phenomenon will lend
us to take more investigations of their roles in lung cancers.
Furthermore, our clinical data analysis showed that
both GABAA receptors (GABRA3) and GABAB receptor
(GABBR2) genes were significantly expressed in the early
Figure 4 (See legend on next page.)
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Figure 4 Kaplan-Meier survival curves of NSCLC patients based on various influential factors. Figure 4A, Overall survival rate in patients
with high expression of GABRA3 was significantly lower than that in patients with high expression. Figure 4B, Overall survival rate in patients with
high expression of GABBR2 was significantly higher than that in patients with low expression. Figure 4E, F, the smokers and the patients in
advanced stage had a shorter survival time. Figure 4C, D, In spite of curve separated, GABRE and pathological grade seemed to have no influence
on survival time. * P < 0.05, ** P < 0.01.
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tients, and the expression was gone in stage III and IV.
This suggests that high level of gene expression of these
GABA receptors may be critical in inhibition of early
stage of cancer cells and this regulatory effect got im-
paired in advanced stage. We speculate that therapeutic
intervention approaches that enhance GABA receptors
maybe beneficial in late stages of NSCLC patients.
We observe a correlation between the high expression
of GABBR2 gene and the greater survival rate in patients
with NSCLC. The overexpression of GABBR2 gene was
mostly seen in female patients who had better outcome.
This suggests that patients with higher level GABBR2
might have better outcome. This observation is consistentTable 3 GABRA3, GABRE and GABBR2 gene expression in
NSCLC tissues compare with paired non-cancerous tissues
Variable N(%) P value
GABRA3 GABRE GABBR2
Total 61(100) 0.030* 0.036* 0.005**
Gender
Male 40(66) 0.040* NS NS
Female 21(34) NS NS 0.008**
Age
<60 36(59) NS NS 0.046*
>60 25(41) NS NS 0.014*
Smoking history
Yes 23(38) NS NS NS
No 38(62) NS NS 0.014*
Histotype
Adenocarcinoma 43(70) NS 0.049* NS
Squamous cell carcinoma 18(30) NS NS 0.020*
Pathological Grade
I, II 48(79) NS NS 0.008**
III 13(21) NS NS NS
Pathological Stage
I, II 47(77) 0.050* NS 0.008**
III 9(15) NS NS NS
IV 5(8) NS NS NS
Pathological grade I: well differentiation, grade II: moderately differentiation,
grade III: poorly differentiation. Pathological stage refers to the 7th Edition of
TNM Classification of Malignant Tumors form UICC. P-value represents the
gene expression of GABA receptor in NSCLC tissues compared with that in
paired non-cancerous controls. NS: no significant difference. *P < 0.05,
** P < 0.01.with previous in vitro data showing that high level
GABBR2 gene expression is associated with inhibition of
cancer cell proliferation [26,39,40].
In contrast, high level GABRA3 gene expression is corre-
lated with cancer cell development [12,35,41], and thus
these patients had worse outcome. We indeed showed that
the higher gene expression of GABRA3 was mostly detected
in those male patients who had a worse prognosis.
Our data was based on a relatively small sample size of
61 patients with NSCLC who were followed for 3–5 years.
Our data suggests that the gene expression of certain
GABA receptor subunits may be useful for prediction of
NSCLC prognosis. We believe that a longer term follow-
up study with larger sample size would be required to con-
firm our current findings.Conclusion
The present study has identified significant gene profiles
of GABA receptors in NSCLC and the gene profiles are
correlated with patients’ survival. Exogenous administra-
tion of GABA can inhibit NSCLC growth by activation on
GABA receptors. Our data suggests that GABA receptors
can modulate cancer cell proliferation and their gene pro-
files may be able to help predict prognosis in patients with
NSCLC.
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